A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

计划入组 120 人 · 首次发布于 2023 年 6 月 22 日

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

计划入组 25 人 · 首次发布于 2019 年 2 月 15 日

A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

计划入组 175 人 · 首次发布于 2025 年 9 月 26 日

NW Roselle

Antiplasmodial and antileishmanial(The University of North Carolina)

MRVAC (The Centre for Research and Production of Vaccines and Biologicals)

INSTITUTE OF EPIDEMIOLOGY, DISEASE CONTROL AND RESEARCH

Bangladesh

NATIONAL INSTITUTE OF DISEASES OF THE CHEST AND HOSPITAL

Bangladesh

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

Nipocalimab Shows Promise in Preventing Hemolytic Disease of the Fetus and Newborn

Nipocalimab Granted FDA Breakthrough Therapy Designation for Sjögren’s Disease

Nipocalimab Granted FDA Breakthrough Therapy Designation for Sjögren’s Disease